DNAPrint Genomics, Inc. (DNAG)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DNAPrint Genomics, Inc. (DNAG) with AI Score 61/100 (Hold). DNAPrint Genomics, Inc. focuses on developing and marketing genetic testing products and services for ancestry, forensics, and pharmaceutical applications. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026DNAPrint Genomics, Inc. (DNAG) Healthcare & Pipeline Overview
DNAPrint Genomics, Inc. specializes in genetic testing products and services, offering ancestry analysis, forensic DNA tools, and genotyping systems. With a focus on serving forensic science, genealogical research, and pharmaceutical development clients, the company operates in the competitive biotechnology sector, marked by rapid innovation and evolving regulatory landscapes.
Investment Thesis
DNAPrint Genomics, Inc. operates in the niche market of genetic testing with products like AncestryByDNA and DNAWitness. The company's gross margin of 31.0% indicates potential for profitability if sales increase. However, the negative P/E ratio and a profit margin of -507.5% highlight significant financial challenges. Growth catalysts include expanding applications of RETINOME in forensics and increased adoption of GenomeLab SNPstream Genotyping System. Key risks involve the company's ability to achieve profitability and manage its operational costs. The high beta of 1.53 suggests the stock is more volatile than the market, adding a layer of risk for investors. Success hinges on effective commercialization and strategic partnerships.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 31.0% indicates potential for profitability with increased sales volume.
- Profit Margin of -507.5% reflects significant operational losses and the need for improved cost management.
- Beta of 1.53 suggests higher volatility compared to the overall market, indicating a riskier investment.
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
- The company serves diverse sectors including forensic science, genealogical research, consumer products, and pharmaceutical development, providing multiple revenue streams.
Competitors & Peers
Strengths
- Specialized genetic testing products and services.
- Expertise in ancestry analysis and forensic DNA tools.
- Diverse customer base across multiple sectors.
- Proprietary technologies like RETINOME and GenomeLab SNPstream.
Weaknesses
- Negative profit margin and financial losses.
- Limited market capitalization and liquidity.
- Dependence on niche markets.
- Unknown disclosure status on the OTC market.
Catalysts
- Upcoming: Potential partnerships with pharmaceutical companies for personalized medicine initiatives.
- Ongoing: Continued development and refinement of RETINOME technology for forensic applications.
- Ongoing: Expansion of direct-to-consumer genetic testing services.
- Upcoming: Potential for increased adoption of GenomeLab SNPstream Genotyping System in research institutions.
Risks
- Ongoing: Negative profit margin and financial losses impacting long-term sustainability.
- Potential: Intense competition in the biotechnology industry.
- Potential: Stringent regulatory requirements and compliance costs.
- Potential: Technological obsolescence of existing products.
- Ongoing: Limited market capitalization and liquidity on the OTC market.
Growth Opportunities
- Expansion of RETINOME Applications in Forensics: DNAPrint Genomics can expand the application of its RETINOME technology in forensic science. The market for forensic DNA analysis is projected to reach $6.1 billion by 2028, growing at a CAGR of 11.2% from 2021. By enhancing the accuracy and capabilities of RETINOME, DNAPrint Genomics can capture a larger share of this market, providing law enforcement agencies with advanced tools for identifying suspects and solving crimes. This expansion requires strategic partnerships with forensic laboratories and continuous innovation in DNA phenotyping technologies.
- Increased Adoption of GenomeLab SNPstream Genotyping System: The GenomeLab SNPstream Genotyping System offers high genotyping rates and efficient data generation, positioning it as a valuable tool for pharmaceutical development and research. The global genotyping market is expected to reach $12.5 billion by 2027. DNAPrint Genomics can drive adoption by targeting research institutions, pharmaceutical companies, and diagnostic labs. Demonstrating the system's cost-effectiveness and superior performance through case studies and collaborations will be crucial for market penetration.
- Strategic Partnerships in Pharmaceutical Development: DNAPrint Genomics can leverage its expertise in genetic testing to form strategic partnerships with pharmaceutical companies. The pharmaceutical industry increasingly relies on genetic data to develop personalized medicine and targeted therapies. By offering customized genotyping services and ancestry analysis, DNAPrint Genomics can support drug discovery and clinical trials. These partnerships can provide a stable revenue stream and enhance the company's reputation in the pharmaceutical sector. The personalized medicine market is projected to reach $2.4 trillion by 2030.
- Direct-to-Consumer Genetic Testing Expansion: DNAPrint Genomics can expand its direct-to-consumer (DTC) genetic testing services, focusing on ancestry analysis and personalized health insights. The DTC genetic testing market is growing, driven by increasing consumer interest in understanding their genetic heritage and health predispositions. By offering user-friendly testing kits and comprehensive reports, DNAPrint Genomics can attract a broader customer base. Marketing efforts should emphasize the accuracy and reliability of the company's testing methods, differentiating it from competitors in the crowded DTC market. The global DTC genetic testing market is expected to reach $6.2 billion by 2027.
- Geographic Expansion into Emerging Markets: DNAPrint Genomics can pursue geographic expansion into emerging markets, where demand for genetic testing services is growing. Countries in Asia-Pacific and Latin America are experiencing increased investment in healthcare infrastructure and research. By establishing partnerships with local distributors and laboratories, DNAPrint Genomics can access these markets and offer its genetic testing products and services to a new customer base. Adapting its products to meet the specific needs and regulatory requirements of each market will be essential for successful expansion.
Opportunities
- Expansion of RETINOME applications in forensics.
- Increased adoption of GenomeLab SNPstream in pharmaceutical development.
- Strategic partnerships with pharmaceutical companies.
- Growth in direct-to-consumer genetic testing market.
Threats
- Intense competition in the biotechnology industry.
- Stringent regulatory requirements and compliance costs.
- Potential for technological obsolescence.
- Economic downturn affecting consumer spending and research budgets.
Competitive Advantages
- Proprietary genetic testing technologies and assays.
- Expertise in forensic DNA analysis and phenotyping.
- Established relationships with forensic science and research institutions.
- Diverse product portfolio catering to multiple market segments.
About DNAG
DNAPrint Genomics, Inc., originally incorporated as Lexington Energy, Inc. in 1983, is a biotechnology company based in Sarasota, Florida, with a subsidiary in Leverkusen, Germany. The company develops and markets genetic testing products and services, catering to a diverse clientele across forensic science, genealogical research, consumer products, and pharmaceutical development. Its product portfolio includes AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; and EuropeanDNA, which reports a customer's proportional basic continental European ancestry. DNAPrint Genomics also offers DNAWitness, a tool used to determine genetic heritage from DNA samples obtained from crime scenes, and RETINOME, which provides a physical portrait of a person of interest based on a DNA sample. Additionally, RETINOME allows for inferring eye color from DNA. The company's GenomeLab SNPstream Genotyping System provides genotyping rates, utilizing a multiplexing format to generate data with minimal reagents. DNAPrint Genomics's focus on specialized genetic testing solutions positions it within a niche segment of the broader biotechnology market, emphasizing innovation and application across multiple sectors.
What They Do
- Develops and markets genetic testing products and services.
- Offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry.
- Provides EurasianDNA, which measures European sub-ancestry.
- Offers EuropeanDNA, which reports proportional basic continental European ancestry.
- Provides DNAWitness to determine genetic heritage from crime scene DNA samples.
- Offers RETINOME, which provides a physical portrait based on DNA samples.
- Offers RETINOME, which allows inferring eye color from DNA.
- Provides GenomeLab SNPstream Genotyping System for genotyping.
Business Model
- Sales of genetic testing kits and services to consumers for ancestry analysis.
- Providing forensic DNA analysis tools and services to law enforcement agencies.
- Offering genotyping services and systems to pharmaceutical companies and research institutions.
- Generating revenue through strategic partnerships and collaborations in the healthcare sector.
Industry Context
DNAPrint Genomics, Inc. operates within the biotechnology industry, a sector characterized by rapid innovation, intense competition, and stringent regulatory oversight. The genetic testing market is experiencing growth, driven by advancements in technology and increasing demand for personalized medicine and ancestry services. DNAPrint Genomics competes with companies offering similar genetic testing services, including ancestry analysis and forensic DNA tools. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and establish strategic partnerships within the evolving landscape.
Key Customers
- Individuals interested in ancestry and genealogy research.
- Law enforcement agencies and forensic laboratories.
- Pharmaceutical companies involved in drug discovery and clinical trials.
- Research institutions conducting genetic studies.
- Consumer product companies utilizing genetic data for product development.
Financials
Chart & Info
DNAPrint Genomics, Inc. (DNAG) stock price: Price data unavailable
Latest News
-
New 52-Week Lows For Monday Morning
· Aug 5, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DNAG.
Price Targets
Wall Street price target analysis for DNAG.
MoonshotScore
What does this score mean?
The MoonshotScore rates DNAG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jatin Patel
CEO
Jatin Patel serves as the CEO of DNAPrint Genomics, Inc., managing a team of 24 employees. Information regarding Mr. Patel's detailed career history, educational background, and previous roles is not available in the provided data. His leadership is focused on guiding the company's strategic direction in the competitive biotechnology sector, emphasizing innovation and market expansion.
Track Record: Due to the limited information available, specific achievements, strategic decisions, and company milestones under Jatin Patel's leadership cannot be detailed. His tenure is marked by the ongoing development and marketing of genetic testing products and services, with a focus on serving forensic science, genealogical research, consumer products, and pharmaceutical development clients.
DNAG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DNAPrint Genomics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to adhere to the same listing standards, potentially increasing the risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The unknown disclosure status increases the risk of investing in DNAG, as investors may lack access to crucial financial information.
- Low Liquidity: As an OTC Other stock, DNAG likely has low trading volume, making it difficult to buy or sell shares efficiently.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight, increasing the potential for fraud or mismanagement.
- Price Volatility: The combination of low liquidity and limited disclosure can lead to significant price swings.
- Going Concern Risk: Companies in the OTC Other tier may face a higher risk of financial distress or bankruptcy.
- Verify the company's financial statements and SEC filings, if available.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's revenue sources and profitability.
- Investigate any legal or regulatory issues involving the company.
- Consult with a financial advisor to assess the risks and potential rewards.
- Check for any news or press releases about the company's performance.
- Longevity in the market since incorporation in 1983.
- Development of specialized genetic testing products.
- Serving diverse sectors including forensic science and pharmaceutical development.
- Subsidiary in Leverkusen, Germany, indicating international presence.
DNAG Healthcare Stock FAQ
What does DNAPrint Genomics, Inc. do?
DNAPrint Genomics, Inc. develops and markets genetic testing products and services, focusing on ancestry analysis, forensic DNA tools, and genotyping systems. The company's offerings include AncestryByDNA, EurasianDNA, EuropeanDNA, DNAWitness, RETINOME, and the GenomeLab SNPstream Genotyping System. These products cater to a diverse clientele, including individuals interested in ancestry, law enforcement agencies, pharmaceutical companies, and research institutions. The company aims to provide innovative genetic solutions for various applications, leveraging its expertise in DNA analysis and phenotyping.
What do analysts say about DNAG stock?
As of 2026-03-18, formal analyst ratings for DNAG stock are unavailable, likely due to its listing on the OTC market and limited market capitalization. Given the company's negative profit margin and financial losses, investors should carefully evaluate the risks and potential rewards. Key valuation metrics such as P/E ratio are not meaningful due to negative earnings. Growth considerations include the company's ability to expand its market reach, secure strategic partnerships, and achieve profitability. Investors should conduct thorough due diligence and consider their risk tolerance before investing.
What are the main risks for DNAG?
The main risks for DNAPrint Genomics, Inc. include its negative profit margin and ongoing financial losses, which raise concerns about its long-term sustainability. The company faces intense competition in the biotechnology industry, requiring continuous innovation and differentiation. Stringent regulatory requirements and compliance costs can also impact profitability. Additionally, the risk of technological obsolescence and the limited market capitalization and liquidity associated with its OTC listing pose significant challenges for investors. The unknown disclosure status further compounds the risks, making it difficult to assess the company's financial health.
What are the key factors to evaluate for DNAG?
DNAPrint Genomics, Inc. (DNAG) currently holds an AI score of 61/100, indicating moderate score. Key strength: Specialized genetic testing products and services.. Primary risk to monitor: Ongoing: Negative profit margin and financial losses impacting long-term sustainability.. This is not financial advice.
How frequently does DNAG data refresh on this page?
DNAG prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DNAG's recent stock price performance?
Recent price movement in DNAPrint Genomics, Inc. (DNAG) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized genetic testing products and services.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DNAG overvalued or undervalued right now?
Determining whether DNAPrint Genomics, Inc. (DNAG) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DNAG?
Before investing in DNAPrint Genomics, Inc. (DNAG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for DNAPrint Genomics, Inc.
- OTC market stocks are inherently more risky than exchange-listed stocks.
- AI analysis pending, indicating further insights may be available in the future.